Promotes deep, restorative delta-wave sleep without next-day grogginess or dependency risk. Addresses perimenopause insomnia at the neurochemical level.
DSIP is a nine-amino acid peptide that modulates sleep architecture by enhancing delta-wave (slow-wave) sleep — the deepest, most restorative phase. It influences the GABAergic system, modulates cortisol and stress hormone patterns, and may interact with endogenous opioid pathways. Unlike benzodiazepines or Z-drugs, DSIP promotes natural sleep patterns without suppressing REM sleep or causing dependency.
Perimenopause insomnia affects up to 60% of women in transition. Estrogen decline directly disrupts sleep architecture by affecting thermoregulation (night sweats), neurotransmitter balance (GABA, serotonin), and cortisol rhythms. DSIP addresses the sleep disruption at the neurochemical level without the cognitive dulling or dependency risk of conventional sleep medications.
DSIP appears well-tolerated in available research. No dependency or withdrawal effects have been reported, which is a key advantage over conventional sleep medications. Mild headache and transient drowsiness have been noted. Human clinical data is limited.
No dependency or withdrawal effects have been reported with DSIP, which distinguishes it from benzodiazepines, Z-drugs, and other conventional sleep medications.
DSIP typically promotes improved sleep quality within the first few administrations. It is usually administered via subcutaneous injection in the evening, 1-2 hours before desired sleep onset.
Part of our Mood, Stress & Sleep hub.
Medical Disclaimer: This profile is for educational purposes only. Always consult a licensed healthcare provider before starting any peptide therapy.
Affiliate Disclosure: Vendor links are affiliate partnerships. Full disclosure →
Take our 60-second quiz for a personalized recommendation.
Find Your Peptide →